Eli Lilly is to expand access to more patients without insurance, expand and reduce the cost of weight loss medication zepbound.

The company has started a vial of 7.5 mg and 10 mg of pipelines sold in the name of the brand Zepbound brand, which costs 599 and $ 699. However, for patients they pay without insurance, it is possible for $ 499 per month. This applies to all fillings delivered in the first 45 days.

In addition, the company reduced the prices of 2.5 mg and 5 mg of vial, respectively for $ 349 and $ 499.

Clito Sima Sistani's sharp speech, losing weight loss hugs

Seeing a significant impetus in profits from Zepbound and Mounjaro – essentially the same medicine, new vials and prices with the use of different FDA, only self-payment pharmacy, LilyDirect self-payment pharmacy.

The company's self-payment program delete third party supply chain institutions, “Allows patients to direct deposits outside insurance.”

Eli Lilly is to expand access to more patients without insurance, expand and reduce the cost of weight loss medication zepbound. (Through Shelby Knowles / Bloomberg / Getty Images)

“Each major medical organization and structure accepts a chronic disease, and the insurance and federal programs do not systematically cover people living with obesity for medical services,” Patrick Jonson, Lilly Contiometabolol power, President of the Contiofabolol power.

Jonson said the company's “will continue to work with all parties to solve this problem,” it will continue to implement new options that improve the availability, “the improvement of the blockbuster drug, which continues to grow in demand and continue to implement” new options. ”

This has expanded Lilly's supply for the first time weight loss medication And reduce the cost to fight effectively in a highly profitable market.

Eli Lilly's Zepbound Type 2 reduces the risk of diabetes, learns learning

The pharmaceutical giant was announced in August, which was the first time in response to a growing student, 2.5 mg and 5 mg were a single-dose vial. In this case, Lilly, doses are “in 50% or more discounts” compared to the list of all other rulers (GLP-1) for obesity.

Indianapolis, Eli Lilly headquarters in Indiana. (ITOK / ISTOCK)

GLP-1 Agonists can improve blood sugar management, but can cause weight loss. Semaglutide, including the active ingredient of Tirzepatide, Wegovy and ozemptic and ozemptic in Novo Nordisk The GLP-1 is considered medicine.

Get the fox work on the way by clicking here

Lilly fell to 45% with new products that contribute to more than $ 3.1 billion in the last financial quarter of this month, mainly contributing to Mounjaro and Zepbound with strong demand.

The company also said that more patients used Lilly Direct, the only used zepbound vials have increased in the three-month period.

“Wholesalers fulfilled orders from pharmacies at a very high level,” said CEO David Ricks told the analysts.

The drug has 2.5 mg, 7.5 mg, 10 mg, 12.5 mg, 12.5 mg, or in a dose pen 0.5 ml in 15 mg.